Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
Computational drug discovery company Nimbus Therapeutics LLC said Abbas Kazimi has replaced Jeb Keiper as CEO, as part of a planned transition. Kazimi had been Nimbus' CBO since 2020. After the $4 billion sale of its TYK2 program to Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in 2022, the biotech’s lead program is NDI-101150, a small molecule targeting HPK1 to treat solid tumors; it recently submitted an IND for WRN inhibitor NDI-219216. After joining Nimbus in 2014 as CBO, Keiper became CFO in 2017 before taking the CEO role in 2018; he holds board seats at Cardurion Pharmaceuticals Inc. and Rome Therapeutics Inc.
Jon Garay Alonso will become CFO of Almirall S.A. (Madrid:ALM), succeeding Mike McCellan who is leaving in September. Garay Alonso is CFO of Camurus AB (SSE:CAMX) and previously held roles at Baxter International Inc. (NYSE:BAX)...